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nsc.ru (M.A. Zenkova).Recent studies demonstrated the ability of artiﬁcial ribonucleases (aRNases, small organic RNA
cleaving compounds) to inactivate RNA-viruses via the synergetic effect of viral RNA cleavage and
disruption of viral envelope [1,2]. Herein, we describe the antiviral activity of aRNases against
DNA-containing vaccinia virus: screening of aRNases of various structures revealed that amphiphilic
compounds built of positively charged 1,4-diazabicyclo[2.2.2] octane substituted at the bridge nitro-
gen atoms with aliphatic residues efﬁciently inactivate this virus. The ﬁrst stage was the destruction
of viral membrane and structure of surface proteins (electron microscopy data). Thus, 1,4-diazabi-
cyclo[2.2.2] octane-based aRNases are novel universal agents inactivating both RNA- and DNA-
containing viruses.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Viruses are extremely diverse in life cycles, morphology, repli-
cation strategies, target cells, etc. Viral genetic material (DNA or
RNA) is covered with protein shell, and this tight RNA(DNA)/pro-
tein complex (capsid) for simple non-enveloped viruses represents
the virus particle, while the structure of more complex viruses may
include lipids and different proteins, covering the capsid. The
application of the universal virus inactivation methods, such as
treatment with formaldehyde, b-propiolactone, and aziridine [3],
or UV-irradiation is limited: the high toxicity of compounds
restricts its wide usage as antiviral agents, and occurring in the
course of inactivation cross linking reaction, which alter the struc-
ture of virus surface epitops [4] restricts their usage upon vaccine
production.
The universal virus inactivating agent should display the antivi-
ral activity in respect to viruses of different structures, therefore it
should interact with various macromolecules: genetic material of
virus [5], proteins and lipids [4]. However, when used for the vac-
cine production, the compound should not dramatically change the
morphology and immunogenic activity of the inactivated virus par-
ticle; moreover, it should not be toxic for personnel.
In this respect, artiﬁcial ribonucleases (aRNases, small
chemical compounds possessing the ribonuclease activity inchemical Societies. Published by E
ical Biology and Fundamen-
osibirsk, Russia. Fax: +7 383
. Fedorova), marzen@niboch.vitro) represent a new promising class of antiviral agents. Three
series of aRNases exhibiting high ribonuclease activity in vitro
designed recently were shown to inactivate the RNA-containing
viruses: the enveloped inﬂuenza A [1] and encephalitis [6]
viruses and non-enveloped Acute bee paralysis virus (ABPV)
[2]. These aRNases were of ABLkCm series, containing imidazole
as catalytic group for the RNA cleavage, and positively charged
1,4-diazabicyclo[2.2.2] octane (DABCO) substituted at the bridge
nitrogens with dodecyl residues, affording the afﬁnity to phos-
phodiester bonds of RNA (ABL3C3, Table 1) [7]; the compounds
of the Dxn series, which contain two similarly substituted DAB-
CO residues and no potentially catalytic groups (Dtr12, Table 1);
and peptide-like molecules containing amino acids as catalytic
groups and hydrophobic substituents (L2–3, Table 1) [8]. It was
demonstrated that the viral RNA of ABL3C3- and Dtr12-inactivated
inﬂuenza virus was cleaved, and the membrane of the inacti-
vated virus particles contained a number of breaks (EM data)
[1], but the surface peplomers were not affected [9]. The inacti-
vation of inﬂuenza virus with peptide-like compound L2–3 being
complete did not result in the prominent cleavage of viral RNA
[9].
Here we screen these aRNases on the ability to inactivate DNA-
containing vaccinia virus. We found that some aRNases completely
inactivate the virus in a short time under physiological conditions.
The concentration proﬁle and time course of virus inactivation
revealed the main stages of the inactivation process and the elec-
tron microscopy (EM) study showed that the virus inactivation
occurred via disruption of viral membrane and, possibly, distortion
of DNA/protein interactions.lsevier B.V. All rights reserved.
Table 1
Inactivation of vaccinia virus by aRNases.
aRNase Structural formulaa Vaccinia virus inactivation
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a The structures of aRNases ABL3C3, Dtr12 and L2–3. The IC50 (cell inhibitory concentration) – the concentration of aRNase at which 50% of CV-1 cells survived after
incubation at 37 C for 24 h were 0.05 mM, 35 lM and >1 mM for ABL3C3, Dtr12, L2–3, respectively. The synthesis and RNA-cleaving activity of the compounds were
described in [7,8,12–15].
b EC (effective concentration) is the concentration of aRNase at which the maximal level of virus inactivation was observed after 24 h of incubation.
c The titer of vaccinia virus estimated after the incubation in the presence of aRNase taken at the effective concentration (24 h at 37 C).
d Control – vaccinia virus was incubated under the same conditions in the absence of aRNases.
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2.1. Enzymes and reagents
The artiﬁcial ribonucleases (aRNases) were synthesized in
the Institute of Chemical Biology and Fundamental Medicine
(Novosibirsk, Russia) byDr. Vladimir Silnikov. The aRNaseswere dis-
solved in 100% DMSO (Sigma, USA) up to 10–50 mM concentration,
and further diluted either with appropriate buffer or MilliQ water.
2.2. Cells
The CV-1 cells were obtained fromRussian cell culture collection
of Institute of Cytology (St. Petersburg, Russia). The cellswere grown
in Dulbecco’s Modiﬁed Eagle Medium (DMEM, Sigma, USA) in the
presence of 5% fetal bovine serum (Serva, USA) and 100 units/ml
penicillin, 100 lg/ml streptomycin, 0.25 lg/ml amphotericin
(Sigma,USA) at 37 C in ahumidiﬁedatmosphere containing5%CO2.
2.3. Virus
The CV-1 cells were grown until conﬂuence in 175 cm2 culture
plates with the initial density 104 cells/ml. The conﬂuent mono-
layer was infected with vaccinia virus at 0.01 multiplicity of infec-
tion (m.o.i) and 1 h after the adsorption at 37 C the cell medium
was replaced with a new portion of DMEM, 5% FBS, 100 units/ml
penicillin, 100 lg/ml streptomycin, 0.25 lg/ml amphotericin. The
plates were incubated for 48 h at 37 C in the humidiﬁed atmo-
sphere containing 5% CO2 until cytopathic effect. The cells were
passed through three cycles of freeze-thawing and then disrupted
to liberate the virus by ultrasonic treatment with Sonopuls HD
2070 (Badelin, Germany) for 20 s. The resulting suspension was
centrifuged for 15 min at 4000 rpm, 4 C, then the virus-containingﬂuid was layered onto the 40% sucrose cushion and centrifuged for
90 min at 18000g, 4 C using the SV-40 rotor. The resulting pellet
was suspended in the buffer containing 50 mM Tris–HCl, pH 9.0, ti-
trated, aliquoted and stored at 20 C.
2.4. Plaque forming unit (FFU) assay
The virus titer was estimated using the in vitro titration tech-
niques described previously [10] and expressed in terms of plaque
forming units per ml (PFU/ml) of the virus suspension.
2.5. Virus inactivation
The vaccinia virus at a concentration 5  105 PFU/ml was incu-
bated in 50 mM Tris–HCl buffer, pH 7.0, in the presence of 200 mM
KCl, 1 mM EDTA and one of the aRNases at a concentration ranging
from 0.05 to 0.25 mM for Dtr12, from 0.05 to 0.5 mM for ABL3C3,
and from 0.1 to 2 mM for L2–3 at 37 C for 0–72 h. As a control
virus suspension incubated under the same conditions but in the
absence of aRNases was used. After 0, 6, 24, 48, 72 h the aliquots
(25 ll) were serially diluted in the DMEM and the titer of virus sus-
pension was estimated by titration as described previously and ex-
pressed as plaque forming units per ml.
2.6. Cytotoxicity assay
The toxicity of aRNases was determined as described previously
[11].
2.7. Electron microscopy
The mixtures containing vaccinia virus (108 PFU/ml) were incu-
bated in the presence of 0.1–0.5 mMABL3C3 as described above for
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ﬁlm was placed on a drop (30 ll) of virus preparation for 30 s
(the excess of the preparation was removed), and then on a drop
of phosphotungstic acid (PTA) for 20 s (the excess of PTA was re-
moved). The dried grids were examined in JEM 1400 transmission
electron microscope (Jeol, Japan) at 80 kV and images were ob-
tained by the Jeol digital camera and Veleta (SIS) digital camera
integrated in Jem 1400 electron microscope.
3. Results
3.1. Antiviral activity of aRNases
The ability of three different aRNases (Table 1) to inactivate
DNA-containing vaccinia virus was tested. The synthesis, biochem-
ical activity of the compounds [7,8,12–15], as well as the antiviral
activity against RNA-containing viruses [1,2,6,9] were described
previously. The vaccinia virus at a concentration 5105 PFU/ml
was incubated at physiological conditions in the presence of one
of the aRNases ABL3C3, Dtr12, L2–3 or in the absence of the com-
pounds for 0–72 h at 37 C. After the incubation the resulting titer
of virus in each reaction mixture was measured using the plaque
forming assay. The screening revealed that aRNases ABL3C3 and
Dtr12 efﬁciently inactivate the virus, while peptide-like aRNase
L2–3 display no antiviral activity (Table 1). aRNases ABL3C3 and
Dtr12 are amphiphilic compounds built of 1,4-diaza-bicyclo[2.2.2]
octane residue, bearing two positive charges at quarternized nitro-
gen atoms substituted with the aliphatic dodecyl residues. The
complete inactivation of virus occurred at a concentration 0.4
and 0.1 mM for ABL3C3 and Dtr12, respectively (Table 1).
To elucidate the mechanism of virus inactivation, the concen-
tration proﬁle and kinetics of virus inactivation by the aRNases
were analyzed. Though for these experiments a very high initial
titer of virus suspension was used (5  105 PFU/ml), it is seen
that virus is rapidly inactivated in the presence of ABL3C3 at a
concentration 0.5, 0.4 and 0.3 mM (Fig. 1A): at this concentration
the complete inactivation of virus was achieved after 6, 24 and
48 h, respectively. This is also true when the virus was incubated
with 0.25 and 0.1 mM Dtr12 (Fig. 1B). With the decrease of con-
centration of aRNases, the inactivation rate also decreased: for
ABL3C3 at concentrations 0.05–0.25 mM and for Dtr12 at 0.05–
0.08 mM virus inactivation was not achieved even after 72 h of
incubation (Fig. 1). The observed dependence of the inactivation
extent on the concentration of aRNase indicates that some inter-
actions between virus particle and aRNase molecules are re-
quired, and the decrease of the number of these contactsFig. 1. The kinetics of vaccinia virus inactivation by aRNases ABL3C3 (A) and Dtr12 (B) at
at each curve. The vaccinia virus was incubated in 50 mM Tris–HCl buffer, pH 7.0, in th
ranging from 0.05 to 0.25 mM (Dtr12), 0.05–0.5 mM (ABL3C3), and 0.1–2 mM (L2–3) at 3
but in the absence of aRNases was used. The error did not exceed 5% for all experimentresulted in the inability of aRNase to inactivate the virus. It
should be specially noted, that ABL3C3 completely inactivated
inﬂuenza virus at a concentration 0.4 mM, and Dtr12 – at con-
centration 0.02 mM [9]. As mentioned, incubation of virus sus-
pension with both compounds resulted in the cleavage of viral
RNA, and the breaks in the membrane of virus particles were de-
tected by EM [1]. Since, the ribonuclease activity of aRNases
could not afford the inactivation of DNA-containing vaccinia
virus, their ability to disrupt viral membrane can be proposed
as the main mechanism of vaccinia virus inactivation.
3.2. The study of the mechanism of virus inactivation
To check this idea we performed the EM study of vaccinia virus
upon inactivation by ABL3C3 and monitored the morphology of
viral particles incubated for 0–18 h with different concentrations
of the compound. Virus incubated under the same conditions but
in the absence of aRNase served as a control.
The vaccinia virus reproduction in the cell culture produces var-
ious types of virus particles: the major part is the intracellular ma-
ture virus, and at a lower extent (less than 3%) – intracellular
enveloped virus [16]. The visualized native virus had the typical
morphology of the poxviruses (Fig. 2A) [17]: the negative staining
revealed virus particles non-transparent for the contrasting agent,
possessing randomly arranged prominent and structured surface
ridges called ‘‘surface tubule elements’’ (STEs) [18]. The parts of
the membrane are visible in the native (Fig. 2A) and control virus
(Fig. 2B). The incubation of the virus without aRNase for 0–18 h
did not visibly change the morphology of the particles (Fig. 2B)
as compared to native virus preparations (Fig. 2A).
The aRNase ABL3C3 at a concentration 0.5 mM caused fast and
complete inactivation of vaccinia virus (Fig. 1A): in the virus prep-
arations incubated for 30 min in the presence of 0.5 mMABL3C3 no
virus particles were detected using the EM, since all particles were
destroyed (primary data not shown). In order to follow the altera-
tions of virus morphology upon inactivation, the virus was incu-
bated in the presence of 0.1 mM ABL3C3, as under these
conditions slow inactivation of virus took place: virus titer de-
creased 10-fold after 72 h of incubation (Fig. 1A). The EM study
of the virus suspension incubated under these conditions for
30 min revealed the distinct damage of the virus particles: the sur-
face tubules lost the structure and looked as fuzzy globular struc-
tures, and ‘‘hollows’’ were visualized on the surface of the viral
particles by the penetration of the contrasting agent (marked with
red arrows, Fig. 2C and D). After the incubation of virus suspension
for 18 h under these conditions (0.1 mM ABL3C3), the particlesdifferent concentration of the compounds. Concentrations of aRNases are indicated
e presence of 200 mM KCl, 1 mM EDTA and one of the aRNases at a concentration
7 C for 0–72 h. As a control virus suspension incubated under the same conditions
s.
Fig. 2. The electron micrographs of the negatively stained preparations of intact vaccinia virus (A), vaccinia virus incubated under the conditions of inactivation for 18 h in the
absence of aRNase (B) and incubated in the presence of 0.1 mM aRNase ABL3C3 for 30 min (C, D) and 18 h (E). Scale bar 100 nm.
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aggregates of non-deﬁned size (Fig. 2E).
4. Discussion
The aRNases were recently shown to display the antiviral activ-
ity against RNA-containing viruses: inactivation of non-enveloped
ABPV was caused by the viral RNA cleavage [2], and inactivation of
the enveloped inﬂuenza virus was due to the RNA cleavage and
membrane distortion [1,9]. As the role of the membranolytic activ-
ity of aRNases in the overall antiviral activity of the compound was
evident, in the present study we tested the ability of aRNases to
inactivate DNA-containing virus. In this respect vaccinia virus rep-
resents a perfect model, as its morphology and life cycle have re-
cently been studied in details [18].
Two aRNases (ABL3C3 and Dtr12) from different series inacti-
vate the vaccinia virus. The structures of these compounds are
sharing similarities: they both contain positively-charged DABCO
residues – one in ABL3C3 and two in Dtr12, as well as hydrophobic
domains – one in ABL3C3 and two in Dtr12. The peptide-like aRN-
ase L2–3, which does not contain DABCO, but contains acid–base
groups, did not inactivate the vaccinia virus.
It is known that the mature intracellular virus posses the mem-
brane, which is fully consistent with a lipidic membrane (5–6 nm
thick) and is covered with the STEs (a) representing the integral
protein extensions; (b) extending 3–5 nm from the viral surface;
(c) corresponding to the outer receptor-binding viral components
[19]. The mature virus enters cells by fusion of the membrane with
the plasma membrane of the host cell, releasing the core (and lat-
eral bodies) into the cytoplasm and activating the virus’ transcrip-
tional program [20].
Since the protein STEs are protruding from the viral membrane,
they might be the ﬁrst target for amphiphilic compounds in thecourse of inactivation: the loose of the proper STE spatial organiza-
tion upon incubation with aRNases observed in the present study
lead to the inability of virus to replicate. It seems likely that aRN-
ases work as some kind of chaotropic agent: after the interaction
with the surface proteins they may interfere with the lipid mem-
brane. EM study performed at different stages of inactivation re-
vealed that aRNase causes viral membrane damage: the breaks
and ‘‘hollows’’ on the surface visible on the EM micrographs of
virus particles appeared at the early stages of interaction, and at
the latest stages resulted in the loss of the integrity of virus parti-
cles required for infectivity. Both, the deterioration of the surface
proteins, as well as the introduction of the membrane breaks could
lead to the distortion of DNA/protein interactions, which all facili-
tate the viral inactivation.
The observed chaotropic activity correlates well with the previ-
ously received data on the ability of aRNases of Dxn and ABLkCm
series to reduce the afﬁnity of aRNase-treated virus to the mono-
clonal antibodies to the surface epitops of inﬂuenza virus [9]. This
ﬁrst step of the interaction of aRNase with inﬂuenza virus followed
by the disruption of the viral envelope (membranolytic activity) as
well as the ribonuclease activity in respect to viral RNA afforded
the effective viral inactivation [9]. In regard to non-enveloped virus
(ABPV) we can propose that acting as a molecular wedge aRNases
Dp12F6 and D3–12 (compounds from the Dxn series) were able to
destabilize the tight nucleoprotein and in synergism with ribonu-
clease cleavage of viral RNA provide the inactivation of the virus
[2]. Therefore, the inactivation of RNA-containing viruses is a result
of all three activities of the compounds (chaotropic, membranolyt-
ic and ribonuclease activities). On the other hand, obtained results
clearly show that chaotropic and membranolytic activities are en-
ough to cause the effective inactivation of DNA-containing virus.
Moreover, the chaotropic and ribonuclease activities are also sufﬁ-
cient for the inactivation of non-enveloped RNA-virus [2]. The
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virus [9] and lack of antiviral activity against ABPV [2] or vaccinia
virus requires special attention.
5. Conclusions
In the present work we demonstrated the ability of two aRNases
to inactivate the DNA-containing virus. The compounds containing
positively charged DABCO residue, substituted at the bridge
nitrogen with aliphatic groups demonstrated the concentration-
dependent proﬁle of virus inactivation. The electron microscopy
study of the inactivated virus preparation revealed that the virus
inactivation occurred via signiﬁcant alteration of the viral
morphology: the surface proteins disorganization and membrane
destruction. Based on the obtained results, we can conclude, that
these aRNases are universal agents for the inactivation of both
RNA- and DNA-containing viruses.
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